Published in Diabetes Care on October 11, 2017
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med (2005) 5.76
Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res (2004) 5.74
Elevated Cardiometabolic Risk Profile Among Young Adults With Diabetes: Need for Action. Diabetes Care (2019) 5.10
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care (2005) 5.10
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet (2012) 4.33
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab (2008) 4.29
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care (2003) 3.37
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80
Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care (2003) 2.69
Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr (2008) 2.55
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes (2011) 2.17
Psychological predictors of physical activity in the diabetes prevention program. J Am Diet Assoc (2006) 2.13
Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes (2010) 2.02
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond) (2008) 1.99
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol (2015) 1.74
Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes (2008) 1.71
Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care (2005) 1.70
Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Ann Epidemiol (2004) 1.64
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) (2010) 1.64
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab (2015) 1.61
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia (2007) 1.60
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab (2016) 1.57
Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause (2011) 1.51
Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care (2006) 1.50
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. Menopause (2013) 1.50
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab (2007) 1.49
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. Diabetes Care (2013) 1.49
Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care (2005) 1.49
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care (2009) 1.48
Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes (2007) 1.45
The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care (2006) 1.44
Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care (2012) 1.42
The impact of lifestyle intervention on sedentary time in individuals at high risk of diabetes. Diabetologia (2015) 1.41
Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care (2005) 1.39
Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care (2000) 1.33
Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia (2008) 1.27
Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. Obesity (Silver Spring) (2009) 1.24
Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension (2002) 1.19
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care (2013) 1.18
Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care (2010) 1.15
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab (2008) 1.14
Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults. J Diabetes Complications (2012) 1.11
The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia (2007) 1.08
Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care (2011) 1.07
HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care (2014) 1.06
Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. Am J Hypertens (2008) 1.06
Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med (2013) 1.06
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care (2012) 1.06
TCF7L2 polymorphism, weight loss and proinsulin:insulin ratio in the diabetes prevention program. PLoS One (2011) 1.04
Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med (2012) 1.00
Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. J Clin Endocrinol Metab (2011) 1.00
Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program. PLoS Genet (2012) 0.99
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2016) 0.97
Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care (2014) 0.97
Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act (2014) 0.93
Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care (2014) 0.92
The diabetes prevention program and its global implications. J Am Soc Nephrol (2003) 0.91
Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care (2014) 0.91
Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care (2014) 0.91
Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet Med (2012) 0.91
Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab (2012) 0.90
Parental longevity and diabetes risk in the Diabetes Prevention Program. J Gerontol A Biol Sci Med Sci (2011) 0.89
Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am J Clin Nutr (2009) 0.89
Diet and exercise in the prevention of diabetes. Int J Clin Pract Suppl (2003) 0.89
Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. Diabetes (2016) 0.89
Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabet Med (2014) 0.88
Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care (2008) 0.88
Depression as a predictor of weight regain among successful weight losers in the diabetes prevention program. Diabetes Care (2012) 0.87
Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet (2013) 0.87
Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One (2012) 0.87
Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes (2014) 0.86
Sex hormone binding globulin and sex steroids among premenopausal women in the diabetes prevention program. J Clin Endocrinol Metab (2013) 0.83
Plasma 25-hydroxyvitamin D and risk of metabolic syndrome: an ancillary analysis in the Diabetes Prevention Program. Eur J Clin Nutr (2014) 0.83
Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program. Obesity (Silver Spring) (2013) 0.82
Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. Diabetes (2015) 0.81
Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med (2014) 0.80
Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab (2013) 0.79
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia (2017) 0.79
Testosterone and depressive symptoms among men in the Diabetes Prevention Program. Psychoneuroendocrinology (2016) 0.79
Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program. Diabetologia (2013) 0.78
Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia (2014) 0.78
Effect of Long-term Metformin and Lifestyle in the Diabetes Prevention Program and its Outcome Study on Coronary Artery Calcium. Circulation (2017) 0.78
Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes (2015) 0.77
The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism (2013) 0.76
Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. Obesity (Silver Spring) (2013) 0.76
Does hormone therapy affect blood pressure changes in the Diabetes Prevention Program? Menopause (2014) 0.76
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism (2015) 0.76
Association between body weight and composition and plasma 25-hydroxyvitamin D level in the Diabetes Prevention Program. Eur J Nutr (2015) 0.76
Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care (2017) 0.76